The effectiveness of the BNT162b2 and ChAdOx1 vaccines against new severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infections requires continuous re-evaluation, …

We report that in a cohort of 45,965 adults, who were receiving either the ChAdOx1 or the
BNT162b2 SARS-CoV-2 vaccines, in those who had no prior infection with SARS-CoV-2, …

Background Decisions about the continued need for control measures to contain the spread
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rely on accurate and up-…

The effectiveness of COVID-19 vaccination in preventing new severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infections in the general community is still unclear. Here, …

Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta
variant has been replaced by the highly transmissible Omicron BA.1 variant, and subsequently …

Antibody responses are an important part of immunity after Coronavirus Disease 2019 (COVID-19)
vaccination. However, antibody trajectories and the associated duration of protection …

Tracking the Emergence of SARS-CoV-2 Alpha Variant in the United Kingdom | NEJM Skip to
main content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare …

Background School-based COVID-19 contacts in England have been asked to self-isolate
at home, missing key educational opportunities. We trialled daily testing of contacts as an …

Understanding the trajectory, duration, and determinants of antibody responses after SARS-CoV-2
infection can inform subsequent protection and risk of reinfection, however large-…

Background A new variant of SARS-CoV-2, B.1.1.7/VOC202012/01, was identified in the UK
in December-2020. Direct estimates of its potential to enhance transmission are limited. …